Benefiting from the sales growth of ONIVYDE, a new pancreatic cancer drug, PharmaEngine reported a net profit of NT$265 million and EPS of NT$1.85 for the first three quarters.

In addition, PEP07 (Chk1 inhibitor), which was introduced through licensing, is scheduled to enter the IND (human clinical trial) and will be launched in Australia by the end of this year or early next year to capture the market for new types of mechanistic anti-cancer drugs.

The company's share price warmed up on the 27th, closing at NT$98.1, up 4.25%, with a chance to return to the NT$100 mark.

In the European market, Germany, the main country, is growing at a rate of 5-10% per year. The company's royalties are usually credited in the last month of each quarter, driving September's revenue to $103 million, up 289% month-on-month, and cumulative first three quarters consolidated revenue of $495 million, up 9.94% year-on-year.

In addition, the market is promising, as Enron has received approval for its mainland drug license and is now testing the waters in the self-financed market. In September, we secured an exclusive global license for PEP07 from Sentinel Oncology for US$140.5 million (approximately NT$4.47 billion) and expect to file for human clinical trials recently.

As PEP07 has been shown in previous clinical trials to inhibit the growth of cancer cells even when used alone, it has attracted the attention of many pharmaceutical companies and we do not rule out the possibility of an early sublicense.

More information please visit www.pharmaengine.com